Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina - PubMed (original) (raw)
. 2005 Mar 15;103(6):1114-21.
doi: 10.1002/cncr.20900.
Affiliations
- PMID: 15712362
- DOI: 10.1002/cncr.20900
Free article
Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina
Brian D Bradbury et al. Cancer. 2005.
Free article
Abstract
Background: It is known that tamoxifen therapy favorably affects blood cholesterol levels and other cardiovascular disease risk factors; however, to our knowledge, few studies to date have reported a lower risk of heart disease for breast carcinoma patients who are treated with tamoxifen.
Methods: A nested, matched, case-control study design was used with data from the General Practice Research Database to examine whether patients with breast carcinoma who had been treated with tamoxifen were at reduced risk of having a first acute myocardial infarction (MI) or of developing angina compared with unexposed women. All women between age 30 years and age 85 years who had been diagnosed with breast carcinoma and treated with tamoxifen, or who had been diagnosed with carcinoma of the bladder or colorectum, or nonmelanoma skin cancer between January 1991 and December 1999 were identified. From this population, all women were identified who had newly diagnosed acute MI or angina that occurred at least 1 year after their cancer diagnosis. Four female control participants were matched to each case based on age (+/- 1 year), date of MI or angina diagnosis (corresponding date for matched controls), and date of cancer diagnosis (+/- 6 months). Odds ratios (ORs) and 95% confidence intervals (95% CIs) were generated using conditional logistic regression, controlling for the matching factors, and adjusting for important risk factors, including body mass index, use of hormone replacement therapy, smoking status, and treated hypertension.
Results: Current users of tamoxifen had a reduced rate ratio of acute MI or angina (adjusted OR, 0.4; 95% CI, 0.2-0.7) compared with nonusers. The effect persisted with increasing cumulative dose and length of use.
Conclusions: The treatment of breast carcinoma with tamoxifen was found to reduce a woman's risk of acute MI or angina during the 5 years of recommended therapy.
Comment in
- Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly diagnosed angina.
Geiger AM, Bernstein L. Geiger AM, et al. Cancer. 2006 Jan 15;106(2):480-1; author reply 481. doi: 10.1002/cncr.21580. Cancer. 2006. PMID: 16311985 No abstract available.
Similar articles
- Effects of smoking and radiotherapy on lung carcinoma in breast carcinoma survivors.
Ford MB, Sigurdson AJ, Petrulis ES, Ng CS, Kemp B, Cooksley C, McNeese M, Selwyn BJ, Spitz MR, Bondy ML. Ford MB, et al. Cancer. 2003 Oct 1;98(7):1457-64. doi: 10.1002/cncr.11669. Cancer. 2003. PMID: 14508833 - Tamoxifen and cataracts: a null association.
Bradbury BD, Lash TL, Kaye JA, Jick SS. Bradbury BD, et al. Breast Cancer Res Treat. 2004 Sep;87(2):189-96. doi: 10.1023/B:BREA.0000041626.76694.85. Breast Cancer Res Treat. 2004. PMID: 15377843 - Stroke risk and tamoxifen therapy for breast cancer.
Geiger AM, Fischberg GM, Chen W, Bernstein L. Geiger AM, et al. J Natl Cancer Inst. 2004 Oct 20;96(20):1528-36. doi: 10.1093/jnci/djh285. J Natl Cancer Inst. 2004. PMID: 15494603 - Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study.
Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, Gabriel SE. Maradit-Kremers H, et al. Arthritis Rheum. 2005 Feb;52(2):402-11. doi: 10.1002/art.20853. Arthritis Rheum. 2005. PMID: 15693010 Review. - The effects of tamoxifen on the female genital tract.
Senkus-Konefka E, Konefka T, Jassem J. Senkus-Konefka E, et al. Cancer Treat Rev. 2004 May;30(3):291-301. doi: 10.1016/j.ctrv.2003.09.004. Cancer Treat Rev. 2004. PMID: 15059652 Review.
Cited by
- Exploring the use of the survivorship consult in providing survivorship care.
Wiljer D, Urowitz S, Jones J, Kornblum A, Secord S, Catton P. Wiljer D, et al. Support Care Cancer. 2013 Aug;21(8):2117-24. doi: 10.1007/s00520-013-1760-4. Epub 2013 Mar 2. Support Care Cancer. 2013. PMID: 23455454 - Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen.
Ntukidem NI, Nguyen AT, Stearns V, Rehman M, Schott A, Skaar T, Jin Y, Blanche P, Li L, Lemler S, Hayden J, Krauss RM, Desta Z, Flockhart DA, Hayes DF; Consortium on Breast Cancer Pharmacogenomics. Ntukidem NI, et al. Clin Pharmacol Ther. 2008 May;83(5):702-10. doi: 10.1038/sj.clpt.6100343. Epub 2007 Aug 22. Clin Pharmacol Ther. 2008. PMID: 17713466 Free PMC article. Clinical Trial. - Cardiovascular events and mortality in a population-based cohort initially diagnosed with ductal carcinoma in situ.
Yoo TK, Park SH, Do Han K, Chae BJ. Yoo TK, et al. BMC Cancer. 2021 Jun 26;21(1):735. doi: 10.1186/s12885-021-08494-0. BMC Cancer. 2021. PMID: 34174850 Free PMC article. - Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study.
Khan NF, Mant D, Carpenter L, Forman D, Rose PW. Khan NF, et al. Br J Cancer. 2011 Nov 8;105 Suppl 1(Suppl 1):S29-37. doi: 10.1038/bjc.2011.420. Br J Cancer. 2011. PMID: 22048030 Free PMC article. - Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors.
Matthews AA, Peacock Hinton S, Stanway S, Lyon AR, Smeeth L, Lund JL, Bhaskaran K. Matthews AA, et al. Heart. 2021 Aug;107(16):1327-1335. doi: 10.1136/heartjnl-2020-317510. Epub 2020 Nov 11. Heart. 2021. PMID: 33177117 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical